Today’s AI Top Pick: PDD

9/14/2026 · Undervalued Emerging screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

View the live PDD price forecast →

Today's pick · Undervalued EmergingPDDBUY NOW9.0 / 109/14/2026

PDD is the cleanest setup in this pool: it passes the screen with room to spare (fwdPe 6.35, PEG 0.65) while pairing best-in-class profitability (profitMargin 20.73%, ROE 22.94%, debtEq 0.01) with 13.53% salesYoY. Unlike most names here, it isn't just cheap — it's a real cash machine trading like a distressed asset after a -31.38% YTD / -38.11% 1yr drawdown, and RSI 30.27 confirms an oversold, hated tape. The multi-timeframe forecast tape is unusually aligned and unusually large: 4h fc_short/mid/long = +43.86 / +59.38 / +63.74, 1d = +18.63 / +34.85 / +34.72, and 1wk = +27.12 / +47.31 / +43.83. All three timeframes point up, and the weekly (usually the noisiest for beaten-down China names) is the strongest confirmation, meaning this isn't a single-bar outlier. bullish_prob = 1.0 and near_term_bullish = 1.0 back the model conviction. Crucially you are NOT chasing. pos_in_21bar_range_pct is 32.53 on 4h, 0 on 1d, and 3.37 on 1wk — price sits at the very bottom of its weekly range with dd_from_21bar_high_pct of -14.27 (1d) and -22.45 (1wk). That is exactly the profile the rules reward: middle/low range position with acceptable drawdown, high forecast magnitude on mid/long horizons. Headline check is benign — the worst recent print is JP Morgan trimming its PT to $95 while maintaining Neutral, which still implies ~23% upside from $77.33 and is not a thesis-breaker. Compare with BABA (Anthropic IP-theft accusation), BILI ($700M convertible + concurrent equity dilution), and RLX (short-seller 'smoke and mirrors' piece) — PDD has the strongest signal AND the cleanest news slate. Waiting risks missing the reversal off the range low; the setup itself IS the pullback.

PDD forecast chart
Entry zone
$75.50 – $78.50 (buy at market near $77.33, add on any dip to the $75–76 shelf)
Stop loss
$70.00 (below the recent weekly low; a break here invalidates the range-low reversal thesis, ~9.5% risk)
First target
$91–92 (roughly the daily fc_short of +18.63%; also aligns with JPM's $95 PT)
Longer target
$110–115 (matches 1wk fc_mid/long of +47/+44% and closes most of the 47.5% analyst targetUpsidePct)
Risks
  • China ADR / VIE regulatory risk — any Beijing or SEC delisting headline can gap the stock 10%+ overnight regardless of fundamentals
  • Temu margin pressure and US tariff/de-minimis exposure — could compress the 20.73% profitMargin that anchors the valuation case
  • RSI 30.27 and weekly -22.45% drawdown mean the trend is still down; catching a falling knife is possible if $70 breaks
  • JPM cut PT to $95 (from higher) and recom is a middling 1.93 vs. peer average ~1.3 — sell-side sentiment is only lukewarm
  • Weekly pos_in_range at 3.37% means little visible support beneath current price; next real bid could be materially lower
Honorable mentions
ONONPEG 0.37, salesYoY 29.34%, profitMargin 12.31%; multi-TF forecasts all green (1d fc_long +64.22, 1wk +29.53) with pos_in_range at 13.01 (1d) / 1.79 (1wk) — deeply oversold with Morgan Stanley reinstating Overweight at $39 and SeekingAlpha noting 'brand heat fears run ahead of evidence.'
BIRKfwdPe 11.01, PEG 0.69, RSI 30.17, dd -34.46% on weekly; all four timeframes forecast up (1d fc_long +36.05, 4h +22.44). Positive 'premium still sells' headline offsets BMO's downgrade to Market Perform. Clean setup but slightly smaller forecast magnitude than PDD.
Full ranking (15)
#SymbolVerdictScoreRead
1PDDBUY NOW9.0Cheapest name (fwdPe 6.35) with 20%+ margins, all TFs green, sitting at weekly range low with +34-64% forecasts and no bad news.
2ONONBUY NOW8.4PEG 0.37 + 29% sales growth, RSI 32, MS Overweight reinstated, and 1d/1wk forecasts +64%/+29% from range lows.
3BIRKBUY NOW8.0RSI 30, -34% weekly drawdown, all four TFs bullish with 1d fc_long +36%, and premium-brand narrative intact.
4ADSKBUY PULLBACK7.2Great software fundamentals (ROE 53.85, grossMargin 85.81) with 1d/1wk forecasts +20-25%, but 4h pos_in_range at 100 — wait for a dip.
5BABABUY PULLBACK6.9PEG 0.28 and 4h fc_long +62.86, but Anthropic IP-theft accusation and 4h pos_in_range at 78.76 argue for patience.
6ADMABUY PULLBACK6.7Elite margins (32.98%) and huge 4h/1d forecasts, but 4h pos_in_range at 100 and weekly fc_short -9.28% flag near-term chase risk.
7FISBUY PULLBACK6.5Screamingly cheap (fwdPe 5.69) with 1wk fc_long +98%, but 1h pos_in_range at 98.88 and near_term_bullish 0.4 say wait.
8ORCLWAIT6.0Solid fundamentals and 1d fc_long +29.71, but 1wk fc_mid/long are -9.24/-8.36 — mixed multi-TF picture.
9TMUSWAIT5.7Best defensive fundamentals but forecast magnitudes are small (1wk fc_long -8.73) and CFO retirement adds uncertainty.
10FUTUWAIT5.5Amazing profitability (42.92% margin, 44% sales growth) but 1wk fc_long -29.82% and 4h pos_in_range 100 kills the entry.
11RLXWAIT5.4Strong 4h/1d forecasts and 59% sales growth, but 'Smoke And Mirrors' short-seller-style piece is a material red flag.
12WAYWAIT5.2Positive AI/subscription story but 1wk fc_short/mid at -7.08/-11.42 and low ROE 3.77 blunt conviction.
13ETORWAIT4.8Cheap and profitable but bullish_prob is null, only 2 TFs available, and a director just sold $3.12M.
14KKRWAIT4.5bullish_prob only 0.6, near_term_bullish 0, and forecast magnitudes are tiny (1d fc_short -2.84%).
15BILIAVOID4.0Forecasts look huge (4h fc_short +74.59) but $700M convertible + concurrent equity placement = material dilution overhang.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord

⚠️ This AI-generated analysis is for informational purposes only and is not financial advice. Forecasts and scores are model outputs that can be wrong; markets involve substantial risk of loss. Do your own research.